Metrics to compare | LONN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLONNPeersSector | |
|---|---|---|---|---|
P/E Ratio | 43.2x | 34.4x | −0.4x | |
PEG Ratio | −0.30 | 0.56 | 0.00 | |
Price/Book | 5.0x | 4.2x | 2.6x | |
Price / LTM Sales | 6.0x | 4.5x | 3.0x | |
Upside (Analyst Target) | 17.3% | 2.5% | 51.3% | |
Fair Value Upside | Unlock | 5.0% | 7.3% | Unlock |
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.